OBJECTIVES: The Turkish Medicines and Medical Devices Agency (TMMDA) gives permission of unlicensed medicine use by patient basis. Authorized wholesalers including Turkish Pharmacists’ Association (TPA) can import the drugs based on the TMMDA`s permission. These medicines are reimbursed by the Social Security Institution (SSI), the main reimbursement agency in Turkey Until 2014 when wholesalers were also authorized, pharmaceuticals under this status could only be imported by the Turkish Pharmacists’ Association (TPA   The aim of this study is to understand the trends in L subgroups (Antineoplastic and immunomodulating agents) of ATC classification system unlicensed medicine consumption between 2011 and 2013 when the TPA was the only authorized supplier. METHODS: Consumption data of L sub-group in the top 100 imported unlicensed medicines with the highest sales share in total expenses of imported off-label use was taken from the TMMDA computer database. L01, L02, L03 and L04 were taken as subgroups. Descriptive analysis was conducted. RESULTS: The analysis showed that the L01 had the highest percentage of active ingredients among L subgroups with 67% share in all L group medicines. The percentage of L01 rose from 67% to 76% between 2011 and 2013. The consumption of L01 rose from 61 million TL to 230 million TL in the same period.   L01 has the highest percentage of unit sales as well. CONCLUSIONS: The cost of imported medicines used in off-label use is increasing every year in Turkey. Some cost-containment measures (especially for L01-antineoplastic agents) should be taken to reduce the cost without risking patients’ access to innovative medicines.